Project Grant R01CA310785
Award Date 5/14/26
Completion Date 4/30/30
Dollars Obligated $651K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- Federal Grant Award Summary Massachusetts General Hospital received a $2.86 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded on September 19, 2025, with a completion date of August 31, 2029. The award funds development and clinical translation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to detect and analyze tumor-derived...
- Federal Grant Award Summary Massachusetts General Hospital received a $684,107 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 18, 2025, with a completion date of July 31, 2030. The grant supports research into the integration of circulating tumor cell (CTC) and nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in...
- Federal Grant Award Summary The National Cancer Institute awarded a $167,500 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Massachusetts Medical School, effective May 1, 2026 through April 30, 2028. This award supports the development and application of HARP-SEQ (a novel, highly sensitive sequencing method) to map 3-methylcytidine (M3C) RNA modifications in messenger RNA at single-nucleotide resolution. The project integrates advanced chemical...
- Federal Grant Award Summary The National Cancer Institute awarded a $176,040 Project Grant to Massachusetts General Hospital under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2025 through June 30, 2027. The award funds research to develop engineered CAR-T (Chimeric Antigen Receptor T) cell therapies capable of overcoming the cancer cell glycocalyx barrier, a protective layer that impedes immune cell recognition and destruction of solid tumors. The research addresses a...
- Federal Grant Award Summary The University of Connecticut Health Center received a $414,585 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for the development and validation of a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform. The research, which commenced on May 6, 2026 and is scheduled for completion by April 30, 2029, focuses on developing noninvasive liquid biopsy technologies for...
- Federal Grant Award Summary Xgenomes Corp. received a $399,816 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) beginning September 1, 2025, with completion scheduled for August 31, 2026. The company is developing a novel circulating tumor DNA (ctDNA) analysis platform that directly measures both genetic mutations and DNA methylation changes with accuracy approximately 100 times greater than current next-generation...
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School $237,023 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop high-throughput technological tools for tracking the fate of prematurely terminated transcripts in cancer cells. The project, which extends through February 28, 2029, focuses on advancing understanding of alternative polyadenylation (APA) events—RNA processing mechanisms that drive oncogenesis independent of DNA...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital (MGH) a Project Grant totaling $188,080 under the Cancer Research Manpower program (CFDA 93.398) on August 22, 2025, with a completion date of August 21, 2027. This award supports a mixed-methods research study titled "Enhancing Access in Pancreatic Cancer: Examining Facilitators and Barriers to Tertiary Referral for Complex Oncologic Surgical Care," which addresses the...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.16 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 14, 2025, with performance through July 31, 2029. The project develops and validates magnetic resonance fingerprinting (MRF) technology to non-invasively image glutamate metabolism in glioblastoma and other brain tumors. The research addresses a critical clinical need by...
- Federal Project Grant Award Summary The National Cancer Institute awarded $1.22M to the University of Massachusetts Boston under its Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, through July 31, 2028. This project grant supports fundamental research to advance understanding of extracellular vesicles (EVs)—cell-derived, membrane-bound structures that carry biomolecules and serve as circulating biomarkers for disease diagnosis and therapeutic delivery. The research...